MAPT and Alzheimer disease: Currently established AD diagnostic biomarkers are based on concentration of amyloid-beta 42 (Aβ42) in cerebrospinal fluid (CSF), CSF total tau (T-tau) and phosphorylated tau (P-tau), and Aβ positron-emission tomography (PET) imaging [4, 5].